Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

NCT07238283 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

662

Enrollment

INDUSTRY

Sponsor class

Conditions

First-line Treatment of Metastatic Pancreatic Cancer

Interventions

DRUG: Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
DRUG: nab-paclitaxel; gemcitabine

Sponsor

Jiangsu HengRui Medicine Co., Ltd.